lobbying_activities: 1351166

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1351166	98bcb415-e52d-4dc8-93d1-3bacf98fd426	Q4	BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC	292972	BOEHRINGER INGELHEIM USA CORPORATION	2012	fourth_quarter	HCR	Gain Act; Shortages; Supply Chain Security; Best Pharmaceuticals for Children Act/Pediatric Research Equity Act Reauthorization; Risk Evaluation and Mitigation Strategies (REMS); Generic Drug User Fee Act; Prescription Drug User Fee Act	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE		590000	0	0	2013-01-22T10:11:02.753000-05:00